We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.57B
AUM Growth
+$29.7M
Cap. Flow
-$123M
Cap. Flow %
-7.84%
Top 10 Hldgs %
52.92%
Holding
277
New
83
Increased
54
Reduced
60
Closed
62

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.2M
2
MNKD icon
MannKind Corp
MNKD
+$15.2M
3
ABUS icon
Arbutus Biopharma
ABUS
+$4.32M
4
TWTR
Twitter, Inc.
TWTR
+$3.59M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.08M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.5M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$10.9M
3
GILD icon
Gilead Sciences
GILD
+$5.35M
4
AGEN
Agenus
AGEN
+$4.63M
5
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
+$3.79M

Sector Composition

Rank Sector Weight
1 Healthcare 9.13%
2 Communication Services 0.29%
3 Materials 0.04%
4 Financials 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BAX icon
26
CALL
Baxter International
BAX
$12.6B
$15M 0.96%
3,973
+906
+30% +$32.9K
WCG
27
CALL
DELISTED
Wellcare Health Plans, Inc.
WCG
$14.7M 0.93%
2,082
+221
+12% +$15.4K
ACAD icon
28
Acadia Pharmaceuticals
ACAD
$4.45B
$13.9M 0.89%
557,013
+130,413
+31% +$3.08M
KERX
29
CALL
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$13.1M 0.84%
10,147
+9,598
+1,748% +$115K
AEGR
30
PUT
DELISTED
Aegerion Pharmaceuticals
AEGR
$12.9M 0.82%
1,820
-1,259
-41% -$96.3K
EW icon
31
CALL
Edwards Lifesciences
EW
$48.2B
$11.2M 0.71%
10,188
– –
CELG
32
PUT
DELISTED
Celgene Corp
CELG
$10.9M 0.7%
1,296
-1,060
-45% -$83.9K
LUMO
33
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$10.7M 0.68%
542
+8
+1% +$1.42K
SRPT icon
34
Sarepta Therapeutics
SRPT
$1.63B
$10.3M 0.66%
507,700
-14,341
-3% -$426K
AEGR
35
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
$9.76M 0.62%
1,375
-825
-38% -$63.1K
IONS icon
36
PUT
Ionis Pharmaceuticals
IONS
$9.14B
$9.31M 0.59%
2,336
+1,334
+133% +$47.5K
MNKD icon
37
PUT
MannKind Corp
MNKD
$1.21B
$8.69M 0.55%
3,336
+163
+5% +$4.14K
AEGR
38
DELISTED
Aegerion Pharmaceuticals
AEGR
$8.28M 0.53%
116,626
-142,493
-55% -$10.9M
CLDX icon
39
CALL
Celldex Therapeutics
CLDX
$2.79B
$8.19M 0.52%
225
-80
-26% -$30.8K
LGND icon
40
CALL
Ligand Pharmaceuticals
LGND
$5.94B
$8.11M 0.52%
+2,470
New +$80.5K
OPK icon
41
PUT
Opko Health
OPK
$1.23B
$7.96M 0.51%
9,427
+2,586
+38% +$26.1K
ACHN
42
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$7.5M 0.48%
22,579
-1,560
-6% -$4.53K
ITMN
43
CALL
DELISTED
INTERMUNE INC
ITMN
$6.17M 0.39%
4,192
+28
+0.7% +$387
BIIB icon
44
PUT
Biogen
BIIB
$30.4B
$6.1M 0.39%
+218
New +$56.4K
GILD icon
45
Gilead Sciences
GILD
$167B
$5.86M 0.37%
78,000
-76,871
-50% -$5.35M
ARNA
46
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
$5.37M 0.34%
918
-1,138
-55% -$59.5K
RPRX
47
PUT
DELISTED
Repros Therapeutics Inc.
RPRX
$5.37M 0.34%
2,935
-2,797
-49% -$52.8K
ANTH
48
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$5.26M 0.34%
214,370
-4,955
-2% -$128K
ALXN
49
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$5.18M 0.33%
389
-727
-65% -$87.2K
MDVN
50
DELISTED
MEDIVATION, INC.
MDVN
$4.79M 0.31%
150,032
-75,666
-34% -$2.29M
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2013 Portfolio in Review

As of Q4 2013, Sabby Management held 277 positions worth $1.57B, up 1.9% from $1.54B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $123M in Q4 2013, closing 62 positions and reducing 60 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $23.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.1% of assets, down from 10% a quarter earlier, followed by Communication Services and Materials.

Against the trend, Sabby Management opened a new position in Arbutus Biopharma worth $4.14M.

  • Sabby Management's largest Q4 2013 buy was Arbutus Biopharma: 519,200 shares worth $4.14M.
  • Sabby Management added most to Teva Pharmaceuticals in Q4 2013, an estimated $17.2M increase.
  • Sabby Management's biggest Q4 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $10.9M.
  • Sabby Management fully exited Vertex Pharmaceuticals in Q4 2013, selling an estimated $23.5M.
  • Sabby Management's ten largest holdings make up 53% of its $1.57B portfolio in Q4 2013.
  • Sabby Management opened 83 new positions and closed 62 in Q4 2013.
  • Sabby Management's portfolio value rose 1.9% quarter-over-quarter to $1.57B.

Based on Sabby Management's 13F filing for Q4 2013, filed 14 Feb 2014.